The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Open accessAbstract
BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation. METHODS: In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety. RESULTS: Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). CONCLUSIONS: Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan was associated with a 13.6% risk of interstitial lung disease (ILD)/pneumonitis, fatal in 2.2% of cases, which needed appropriate and rapid diagnosis and treatment.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan (DS-8201), an ADC composed of trastuzumab, a cleavable tetrapeptide-based linker and a cytotoxic topoisomerase I inhibitor, demonstrated a response rate of 60.6% (95% CI 53.4-68.0) and an unprecedented median PFS of 16.4 months (95% CI 12.7—not reached) in a phase II study of heavily pretreated patients (median six lines, range 2-27 lines, including trastuzumab and T-DM1).64”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Self-citationPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., van de Vijver, M. J., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. O. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,190
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,163
Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009) · Clinical Medicine & Research · doi:10.3121/cmr.2009.825 · Cited by 1,023
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- 10.3121/cmr.2008.825 · DOI
- Modi S Tsurutani J Takahashi S et al. Safety and efficacy results from a phase 1 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2 expressing metastatic breast cancers. Presented at the 2017 San Antonio Breast Cancer Symposium San Antonio TX December 5–9 2017.
Cited by
Sorted by citations
Lyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,457
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M. J., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,871
Self-citationLoibl, S., Poortmans, P. M., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,791
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Self-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D. M., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C. T., ELIAS, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,602
Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R. A., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,523
Self-citationTreatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., Angelis, C. D., Licata, L., & Gianni, L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,450
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“1 score: 4 There are, however, no data on the use of this combination after progression on pertuzumab or T-DM1.”
BackgroundSelf-citationTrastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,257
Self-citationUnlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209
Self-citationTargeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D. A. E., & Janne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,092
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L. A., Saltos, A. N., Felip, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,068
Self-citationIntratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W., Poortmans, P., Regan, M. M., Senn, H.-J., Winer, E. P., Gnant, M. I., Aebi, S. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 875
Deciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 792
Pathogenesis of Triple-Negative Breast Cancer
Derakhshan, F., & Reis-Filho, J. S. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042420-093238 · Cited by 714
Hurvitz, S. A., Hegg, R., Chung, W., Im, S., Jacot, W., Ganju, V., Chiu, J. W. Y., Xu, B., Hamilton, E. P., Madhusudan, S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02420-5 · Cited by 714
Self-citationSaura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00147 · Cited by 604
Self-citationDenkert, C., Seither, F., Schneeweiß, A., Link, T., Blohmer, J., Just, M., Wimberger, P., Forberger, A., Tesch, H., Jackisch, C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00301-6 · Cited by 562
Lyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 541
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 553
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Xiao, L., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 480
Self-citationMechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Siena, S., Bartolomeo, M. D., Raghav, K. P. S., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Élez, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00086-3 · Cited by 436
Self-citationBreast cancer: an up‐to‐date review and future perspectives
Hong, R., & Xu, B. (2022) · 癌症：英文版 · doi:10.1002/cac2.12358 · Cited by 453
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 411
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Tarantino, P., Pestana, R. C., Corti, C., Modi, S., Bardia, A., Tolaney, S. M., Cortés, J., Soria, J., & Curigliano, G. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21705 · Cited by 404
Self-citationAndré, F., Park, Y. H., Kim, S., Takano, T., Im, S., Borges, G. D. S., Lima, J. P. D. S. N., Aksoy, S., Gregori, J. G., Laurentiis, M. D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00725-0 · Cited by 406
Self-citationBartsch, R., Berghoff, A. S., Furtner, J., Marhold, M., Bergen, E. S., Roider‐Schur, S., Starzer, A. M., Forstner, H., Rottenmanner, B., Dieckmann, K. U., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01935-8 · Cited by 400
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Marchiò, C., Annaratone, L., Marques, A., Casorzo, L., Berrino, E., & Sapino, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.016 · Cited by 396
Tsurutani, J., Iwata, H., Krop, I. E., Janne, P. A., Doi, T., Takahashi, S., Park, H., Redfern, C. H., Tamura, K., Wise-Draper, T. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1014 · Cited by 359
Self-citationBreast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 370
Goto, K., Goto, Y., Kubo, T., Ninomiya, K., Kim, S., Planchard, D., Ahn, M., Smit, E. F., Langen, A. J. D., Pérol, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01361 · Cited by 361
Self-citationEmerging therapeutic agents for advanced non-small cell lung cancer
Chen, R., Manochakian, R., James, L. E., Azzouqa, A., Shi, H., Zhang, Y., Zhao, Y., Zhou, K., & Lou, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00881-7 · Cited by 347
Okajima, D., Yasuda, S., Maejima, T., Karibe, T., Sakurai, K., Aida, T., Toki, T., Yamaguchi, J., Kitamura, M., Kamei, R., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0206 · Cited by 339
Precision Medicine: Disease Subtyping and Tailored Treatment
Wang, R. C., & Wang, Z. (2023) · Cancers · doi:10.3390/cancers15153837 · Cited by 354
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 341
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 338
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Zhao, X., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 331
Current State of Breast Cancer Diagnosis, Treatment, and Theranostics
Bhushan, A., Gonsalves, A., & Menon, J. U. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050723 · Cited by 339
Janne, P. A., Baik, C., Su, W.-C., Johnson, M. L., Hayashi, H., Nishio, M., Kim, D.-W., Koczywas, M., Gold, K. A., Steuer, C. E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0715 · Cited by 313
Self-citationHER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Schlam, I. M., & Swain, S. M. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00265-1 · Cited by 308
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Tong, J. T. W., Harris, P. W. R., Brimble, M. A., & Kavianinia, I. (2021) · Molecules · doi:10.3390/molecules26195847 · Cited by 302
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Li, B. T., Michelini, F., Misale, S., Cocco, E., Baldino, L., Cai, Y., Shifman, S. G., Tu, H., Myers, M. L., Xu, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0215 · Cited by 293
Self-citationPowell, C. A., Modi, S., Iwata, H., Takahashi, S., Smit, E. F., Siena, S., Chang, D.-Y., Macpherson, E., Qin, A., Singh, J. C., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100554 · Cited by 298
Self-citationAntitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 288
Designing antibodies as therapeutics
Carter, P. J., & Rajpal, A. (2022) · Cell · doi:10.1016/j.cell.2022.05.029 · Cited by 282
Trastuzumab Deruxtecan: First Approval
Keam, S. J. (2020) · Drugs · doi:10.1007/s40265-020-01281-4 · Cited by 270
Cardoso, F., Paluch–Shimon, S., Schumacher-Wulf, E., de Matos, L. V., Gelmon, K. A., Aapro, M., Bajpai, J., Barrios, C. H., Bergh, J. C. S., Bergsten-Nordström, E., et al. (2024) · The Breast · doi:10.1016/j.breast.2024.103756 · Cited by 276
Self-citationPayload diversification: a key step in the development of antibody–drug conjugates
Conilh, L., Sadilkova, L., Viricel, W., & Dumontet, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01397-y · Cited by 257
Tolaney, S. M., Wardley, A. M., Zambelli, S., Hilton, J. F., Troso-Sandoval, T. A., Ricci, F., Im, S., Kim, S., Johnston, S. R. D., Chan, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30112-1 · Cited by 260
Self-citationAntibody–drug conjugates in solid tumors: a look into novel targets
Criscitiello, C., Morganti, S., & Curigliano, G. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01035-z · Cited by 259
Pérez-García, J. M., Batista, M. V., Cortez, P., Ruíz‐Borrego, M., Cejalvo, J. M., de la Haba-Rodríguez, J., Garrigós, L., Racca, F., Servitja, S., Blanch, S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac144 · Cited by 249
Conte, P., Ascierto, P. A., Patelli, G., Danesi, R., Vanzulli, A., Sandomenico, F., Tarsia, P., Cattelan, A. M., Comes, A., Laurentiis, M. D., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100404 · Cited by 241
Ferraro, E., Drago, J. Z., & Modi, S. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01459-y · Cited by 238
Self-citationClaudin 18.2 as a novel therapeutic target
Nakayama, I., Qi, C., Chen, Y., Nakamura, Y., Shen, L., & Shitara, K. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00874-2 · Cited by 243
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 238
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
Shi, F., Liu, Y., Zhou, X., Shen, P., Xue, R., & Zhang, M. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2069883 · Cited by 227
Asleh, K., Riaz, N., & Nielsen, T. O. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02476-1 · Cited by 235
Novel HER2–targeted therapies for HER2–positive metastatic breast cancer
Kunte, S., Abraham, J., & Montero, A. J. (2020) · Cancer · doi:10.1002/cncr.33102 · Cited by 227
Emerging Targeted Therapies for HER2-Positive Breast Cancer
Mercogliano, M. F., Bruni, S., Mauro, F. L., & Schillaci, R. (2023) · Cancers · doi:10.3390/cancers15071987 · Cited by 214
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Riccardi, F., Bo, M. D., Macor, P., & Toffoli, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274088 · Cited by 207
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208
Swain, S. M., Nishino, M., LANCASTER, L. H., Li, B. T., Nicholson, A. G., Bartholmai, B. J., Naidoo, J., Schumacher-Wulf, E., Shitara, K., Tsurutani, J., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102378 · Cited by 206
Self-citationA review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Liu, K., Li, M., Li, Y., Li, Y., Chen, Z., Tang, Y., Yang, M., Deng, G., & Liu, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01963-7 · Cited by 196
Horisawa, N., Adachi, Y., Takatsuka, D., Nozawa, K., Endo, Y., Ozaki, Y., Sugino, K., Kataoka, A., Kotani, H., Yoshimura, A., et al. (2021) · Breast Cancer · doi:10.1007/s12282-021-01303-3 · Cited by 196
Self-citationShimizu, T., Sands, J. M., Yoh, K., Spira, A. I., Garon, E. B., Kitazono, S., Johnson, M. L., Meric‐Bernstam, F., Tolcher, A. W., Yamamoto, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00059 · Cited by 195
Zhu, Y., Liu, K., Wang, K., & Zhu, H. (2023) · Cancer · doi:10.1002/cncr.34507 · Cited by 192
Bystander effect of antibody–drug conjugates: fact or fiction?
Giugliano, F., Corti, C., Tarantino, P., Michelini, F., & Curigliano, G. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01266-4 · Cited by 196
Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence
Gogia, P., Ashraf, H., Bhasin, S., & Xu, Y. (2023) · Cancers · doi:10.3390/cancers15153886 · Cited by 198
Bardia, A., Krop, I. E., Kogawa, T., Juric, D., Tolcher, A. W., Hamilton, E. P., Mukohara, T., Lisberg, A., Shimizu, T., Spira, A. I., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01909 · Cited by 188
Self-citationTrial watch: IDO inhibitors in cancer therapy
Naour, J. L., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 195
Giordano, S. H., Franzoi, M. A., Temin, S., Anders, C. K., Chandarlapaty, S., Crews, J. R., Kirshner, J. J., Krop, I. E., Lin, N., Morikawa, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00519 · Cited by 195
Self-citationCurrent and Future Management of HER2-Positive Metastatic Breast Cancer
Martínez‐Sáez, O., & Prat, A. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00172 · Cited by 192
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178
Evolving standards of care and new challenges in the management of HER2‐positive breast cancer
Choong, G. M. Y., Cullen, G. D., & O'Sullivan, C. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21634 · Cited by 179
Huppert, L. A., Gümüşay, Ö., Idossa, D. W., & Rugo, H. S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 188
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
Tarantino, P., Modi, S., Tolaney, S. M., Cortés, J., Hamilton, E. P., Kim, S., Toi, M., André, F., & Curigliano, G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3595 · Cited by 178
Self-citationKumagai, K., Aida, T., Tsuchiya, Y., Kishino, Y., Kai, K., & Mori, K. (2020) · Cancer Science · doi:10.1111/cas.14686 · Cited by 175
Management of brain metastases according to molecular subtypes
Soffietti, R., Ahluwalia, M. S., Lin, N., & Rudà, R. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0391-x · Cited by 175
Narayan, P., Osgood, C. L., Singh, H., Chiu, H.-J., Ricks, T. K., Chow, E. C. Y., Qiu, J., Song, P., Yu, J., Namuswe, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4557 · Cited by 172
Ma, Y., Huang, Y., Zhao, Y., Zhao, S., Xue, J., Yang, Y., Fang, W., Guo, Y., Han, Y., Yang, K., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00159-1 · Cited by 172
Self-citationSzwed, M., & Marczak, A. (2024) · Cancers · doi:10.3390/cancers16061156 · Cited by 177
Dempsey, N. G., Rosenthal, A., Dabas, N., Kropotova, Y., Lippman, M. E., & Bishopric, N. H. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06280-x · Cited by 171
Mechanisms of Resistance to Antibody-Drug Conjugates
Khoury, R., Saleh, K., Khalife, N., Saleh, M. A., Chahine, C., Ibrahim, R., & Cesne, A. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119674 · Cited by 174
Skidmore, L. K., Sakamuri, S., Knudsen, N. A., Hewet, A. G., Milutinovic, S., Barkho, W., Biroc, S. L., Kirtley, J., Marsden, R., Storey, K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1004 · Cited by 166
Raghav, K. P. S., Siena, S., Takashima, A., Kato, T., den Eynde, M. V., Pietrantonio, F., Komatsu, Y., Kawakami, H., Peeters, M., André, T., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00380-2 · Cited by 169
Costa, R. L. B., & Czerniecki, B. J. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0153-3 · Cited by 169
Mechanisms of Resistance to Antibody–Drug Conjugates
Abelman, R. O., Wu, B., Spring, L. M., Ellisen, L. W., & Bardia, A. (2023) · Cancers · doi:10.3390/cancers15041278 · Cited by 165
Exploration of the antibody–drug conjugate clinical landscape
Maecker, H. L., Jonnalagadda, V. S., Bhakta, S., Jammalamadaka, V., & Junutula, J. R. (2023) · mAbs · doi:10.1080/19420862.2023.2229101 · Cited by 158
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Sasso, J. M., Tenchov, R., Bird, R. E., Iyer, K. A., Ralhan, K., Rodríguez, Y., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00374 · Cited by 162
Wahby, S., Fashoyin‐Aje, L. A., Osgood, C. L., Cheng, J., Fiero, M. H., Zhang, L., Tang, S. W., Hamed, S. S., Song, P., Charlab, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3119 · Cited by 159
Self-citationThe Exciting New Field of HER2-Low Breast Cancer Treatment
Eiger, D., Agostinetto, E., Saúde-Conde, R., & de Azambuja, E. (2021) · Cancers · doi:10.3390/cancers13051015 · Cited by 156
Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
Chen, Y. A., Xu, Y., Shao, Z., & Yu, K. (2022) · 癌症：英文版 · doi:10.1002/cac2.12387 · Cited by 158
Kalinsky, K. M., Diamond, J. R., Vahdat, L. T., Tolaney, S. M., Juric, D., O’Shaughnessy, J., Moroose, R. L., Mayer, I. A., Abramson, V. G., Goldenberg, D. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.004 · Cited by 152
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Kreutzfeldt, J., Rozeboom, B. J., Dey, N., & De, P. K. (2020) · PubMed Central · Cited by 151
Kang, M. S., Kong, T. W. S., Khoo, Y. X. J., & Loh, T. (2021) · Chemical Science · doi:10.1039/d1sc02973h · Cited by 153
Wang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 157
Metadata
- Authors
- Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., Sohn, J., Denduluri, N., Perrin, C., Aogi, K., Tokunaga, E., Im, S.-A., Lee, K. S., Hurvitz, S. A., Cortes, J., Lee, C., Chen, S., Zhang, L., Shahidi, J., Yver, A., & Krop, I.
- Affiliations
- SHOWA Medical University (JP)
- From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 610-621
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7458671
- OpenAlex
- W2996630100
- Cited by
- 2,006
- References
- 40
- Citations by year
- 2026: 234 · 2025: 266 · 2024: 317 · 2023: 355 · 2022: 345 · 2021: 312 · 2020: 174
- FWCI
- 86.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Daiichi-Sankyo
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- trastuzumab deruxtecan, HER2-positive breast cancer, metastatic breast cancer, trastuzumab emtansine, antibody-drug conjugates, previously treated patients, objective response rate, progression-free survival, neutropenia, dose escalation, topoisomerase I inhibitor, HER2-targeted therapy, treatment efficacy and safety
- MeSH terms
- Trastuzumab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Camptothecin, Female, Humans, Middle Aged, Lung Diseases, Interstitial, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Kaplan-Meier Estimate, Intention to Treat Analysis, Consolidation Chemotherapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
